Primary Endpoint

In Detail

A primary endpoint is the main outcome that a clinical trial is designed to measure and the result upon which the success or failure of the trial is judged. It is defined in the study protocol before the trial begins and must be specified in the trial registration on ClinicalTrials.gov. The choice of primary endpoint is one of the most critical decisions in trial design because it determines the sample size, study duration, and statistical analysis plan. Common primary endpoints include overall survival (time until death), progression-free survival (time until disease worsens), objective response rate (percentage of patients whose tumors shrink), and patient-reported outcomes such as pain scores or quality of life measures. The FDA has specific guidance on acceptable primary endpoints for different disease areas. For cancer, overall survival is considered the gold standard, but the agency increasingly accepts surrogate endpoints like progression-free survival for accelerated approval. A trial typically has only one primary endpoint, though some trials use co-primary endpoints (two endpoints that both must show statistical significance) or composite endpoints (combining multiple outcomes into a single measure). The statistical analysis is powered around the primary endpoint — meaning the trial enrolls enough participants to detect a meaningful difference in this specific outcome with a predetermined level of confidence. Results on the primary endpoint are what regulators, physicians, and patients look to first when evaluating whether a new treatment represents a meaningful advance.